首页> 外文期刊>Iranian Journal of Microbiology >Distribution of ciprofloxacin-resistance genes among ST131 and non-ST131 clones of Escherichia coli isolates with ESBL phenotypes isolated from women with urinary tract infection
【24h】

Distribution of ciprofloxacin-resistance genes among ST131 and non-ST131 clones of Escherichia coli isolates with ESBL phenotypes isolated from women with urinary tract infection

机译:Distribution of ciprofloxacin-resistance genes among ST131 and non-ST131 clones of Escherichia coli isolates with ESBL phenotypes isolated from women with urinary tract infection

获取原文
获取原文并翻译 | 示例
           

摘要

Background and Objectives: Escherichia coli (E. coli) sequence type 131 (ST131) is associated with extended-spectrum beta-lactamase (ESBL) production and fluoroquinolone resistance. This study aimed to investigate the prevalence of ST131, ESBL, and plasmid-mediated quinolone resistance (PMQR) genes in the ciprofloxacin-resistant (CIP R ) and ESBL producers from women with UTI. Materials and Methods: The CIP-resistant ESBL producing (CIP R /ESBL + ) E. coli isolates were screened for ST131-by specific PCR of mdh and gyrB. The ESBL and PMQR genes were screened by single PCR. The ST131 and non-ST131 isolates were selected to determine the mutations of gyrA and parC using PCR and sequencing, and also their genetic background by the Pasteur-MLST scheme. Results: Overall, 55 (33/60) CIP R /ESBL + isolates were identified as ST131 (94 O25b-ST131). Resistance rate to ampicillin-sulbactam (70), aztreonam (97) and gentamicin (61), the prevalence of aac(6′)-Ib-cr (66), bla CTX-M-15 (82), the profile of qnrS + aac(6′)-Ib-cr (30), and the double mutation in the parC was significantly higher in ST131 than non-ST131 isolates. The coexistence of PMQR and ESBL genes was found in more than 50 of ST131 and non-ST131 isolates. ST131 isolates differentiated into PST43 and PST506. Conclusion: Management of women with UTI caused by the CIP R /ESBL + isolates (ST131) co-harbored PMQR, ESBL, and chromosomal mutations, is important for their effective therapy.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号